Showing 821-830 of 1789 results for "".
Hyperpigmentation in Darker Skin Types: A Review of Current Treatments
https://practicaldermatology.com/programs/practical-dermatology/hyperpigmentation-in-darker-skin-types-a-review-of-current-treatments/24217/Pigmentary disorders are a leading concern for patients and consumers worldwide.Diet and Inflammation in Dermatology
https://practicaldermatology.com/topics/other-dermatitis/diet-and-inflammation-in-dermatology/23008/Food for Thought: A Closer Look at Diet and Acne
https://practicaldermatology.com/topics/general-topics/food-for-thought-a-closer-look-at-diet-and-acne/21308/Rosacea: A Closer Look at the Latest Treatment Options
https://practicaldermatology.com/programs/practical-dermatology/rosacea-a-closer-look-at-the-latest-treatment-options/23983/The latest treatments and expanded, responsible choices for treating patients with rosacea.Shedding Some Light on Hair Loss
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/shedding-some-light-on-hair-loss/23191/A look at the evolution of laser- and LED-assisted hair regrowth and the future of light therapy in the treatment of androgenetic alopeciaTherapies in Practice: New Options for Ichthyosis Vulgaris
https://practicaldermatology.com/topics/general-topics/therapies-in-practice-new-options-for-ichthyosis-vulgaris/21933/Emerging data confirm that atopic dermatitis and ichthyosis share pathogenic traits, suggesting a role for barrier repair formulations in management.What’s New in Topical Treatment for Actinic Keratosis?
https://practicaldermatology.com/topics/skin-cancer-photoprotection/whats-new-in-topical-treatment-for-actinic-keratosis/23483/An overview of the latest developments in treatment of these common precancerous lesions.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muExperts React to Latest Benzene Analysis
https://practicaldermatology.com/videos/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improvIn The Pipeline: Phase 1, 2, and 3
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/pipeline-phase-1-2-and-3/29087/This summary provides the latest news on of some of the recent Phase 1, Phase 2, and Phase 3 clinical studies for psoriasis treatments.